{"id":"ixabepilone-capecitabine","safety":{"commonSideEffects":[{"rate":"60-70","effect":"Peripheral neuropathy"},{"rate":"50-60","effect":"Neutropenia"},{"rate":"40-50","effect":"Anemia"},{"rate":"50-60","effect":"Fatigue"},{"rate":"40-50","effect":"Nausea"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Hand-foot skin reaction"},{"rate":"20-30","effect":"Myalgia/arthralgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ixabepilone is a microtubule-stabilizing agent (taxane analog) that binds to β-tubulin and prevents microtubule depolymerization, disrupting mitotic spindle formation and inducing apoptosis. Capecitabine is a fluoropyrimidine carbamate that is metabolized to 5-fluorouracil, which inhibits thymidylate synthase and disrupts DNA synthesis. The combination exploits complementary mechanisms of action for enhanced antitumor efficacy.","oneSentence":"Ixabepilone stabilizes microtubules to prevent cell division, while capecitabine is a prodrug that converts to fluorouracil to inhibit DNA synthesis, together providing synergistic cytotoxic activity against cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:41.711Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic or locally advanced breast cancer"},{"name":"HER2-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT01349088","phase":"PHASE1, PHASE2","title":"Investigational Drug in Combination With Two Chemotherapy Drugs in Women With Locally Recurrent or Metastatic Breast Cancer","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2013-12","conditions":"Breast Cancer, Metastatic Breast Cancer, Stage IV Breast Cancer","enrollment":""},{"nctId":"NCT02915744","phase":"PHASE3","title":"A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2016-11","conditions":"Metastasis, Breast Cancer","enrollment":178},{"nctId":"NCT01492101","phase":"PHASE3","title":"The BEACON Study (Breast Cancer Outcomes With NKTR-102)","status":"COMPLETED","sponsor":"Nektar Therapeutics","startDate":"2011-12","conditions":"Locally Recurrent Breast Cancer, Metastatic Breast Cancer","enrollment":852},{"nctId":"NCT00082433","phase":"PHASE3","title":"Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2003-11","conditions":"Cancer, Breast Cancer","enrollment":1221},{"nctId":"NCT00080301","phase":"PHASE3","title":"Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2003-09","conditions":"Breast Cancer, Metastases","enrollment":752},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":"Breast Cancer Organoids","enrollment":300},{"nctId":"NCT01156753","phase":"PHASE2","title":"A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer","status":"COMPLETED","sponsor":"Celldex Therapeutics","startDate":"2010-07","conditions":"Breast Cancer","enrollment":120},{"nctId":"NCT00207129","phase":"PHASE1","title":"Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2004-10","conditions":"Advanced Solid Tumors, Neoplasms","enrollment":25},{"nctId":"NCT00049244","phase":"PHASE1","title":"BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer","status":"UNKNOWN","sponsor":"R-Pharm","startDate":"2002-09","conditions":"Breast Cancer","enrollment":""},{"nctId":"NCT00080262","phase":"PHASE2","title":"Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2004-02","conditions":"Breast Cancer, Metastases","enrollment":125},{"nctId":"NCT00568022","phase":"PHASE1","title":"A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"R-Pharm","startDate":"2008-02","conditions":"Breast Cancer","enrollment":9},{"nctId":"NCT00634088","phase":"PHASE1","title":"Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer","status":"TERMINATED","sponsor":"R-Pharm","startDate":"2008-06","conditions":"Locally Advanced or Metastatic Breast Cancer","enrollment":13},{"nctId":"NCT00546364","phase":"PHASE2","title":"Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer","status":"TERMINATED","sponsor":"R-Pharm","startDate":"2008-02","conditions":"Breast Neoplasms","enrollment":62},{"nctId":"NCT00798252","phase":"PHASE1","title":"Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-03","conditions":"Advanced Cancer","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BMS-247550","IXEMPRA","Epothilone","IXEMPRA®"],"phase":"phase_3","status":"active","brandName":"Ixabepilone + Capecitabine","genericName":"Ixabepilone + Capecitabine","companyName":"R-Pharm","companyId":"r-pharm","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ixabepilone stabilizes microtubules to prevent cell division, while capecitabine is a prodrug that converts to fluorouracil to inhibit DNA synthesis, together providing synergistic cytotoxic activity against cancer cells. Used for Metastatic or locally advanced breast cancer, HER2-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}